Nepafenac ophthalmic suspension is a topical non-steroidal anti-inflammatory drug (NSAID) approved in the US and Europe for prevention and treatment of post-operative pain and inflammation associated with cataract surgery, and recently approved in Europe for reduction in risk of post-operative macular oedema associated with cataract surgery in diabetic patients. Unlike conventional NSAIDs, nepafenac is a prodrug that is uncharged and this results in great corneal permeability. Experimental studies on nepafenac demonstrated enhanced permeability compared with other NSAIDs, and rapid bioactivation to amfenac by intraocular hydrolases within ocular tissues including ciliary body epithelium, retina, choroid and cornea, which results in targeted delivery of active drug to anterior and posterior segments.
During ophthalmic surgery, surgical trauma causes activation of cyclo-oxygenase (COX) COX-1 and COX-2, which metabolise arachidonic acid to prostaglandins (PGs). PGs are mediators of the inflammatory response, and increased production of these molecules can result in discomfort, pain and ocular inflammation. As inhibitors of PGs, non-steroidal anti-inflammatory drugs (NSAIDs) are often employed by ophthalmic surgeons to provide anti-inflammatory control post-surgery and work synergistically with steroid therapy to minimise pain and inflammation following ocular surgery, 1,2 albeit by different mechanisms.
NSAIDS primarily act on cyclo-oxygenase-1 (COX-1) and COX-2 to minimise PG formation, 3 and while steroids also reduce PG synthesis, this is due to the inhibition of phospholipase A2. 4 Moreover, NSAID treatment has been demonstrated to have a beneficial effect on visual outcomes, 5 preventing macular oedema after cataract surgery, however, it is essential to attain therapeutic concentrations in the posterior chamber to obtain the effect of NSAID treatment on the target retina tissue. Thus, for maximum therapeutic benefit, the ideal NSAID is one that reaches therapeutic levels in both the aqueous humour and in the posterior segment tissues. Nepafenac is a NSAID with a unique prodrug structure that has superior corneal permeability to other currently available NSAIDs. 6 This review aims to consider the properties, existing efficacy and safety data, other possible indications of nepafenac in inflammation treatment and the advantages it provides over existing NSAIDs in cataract surgery.
Mode of Action of Nepafenac
Nepafenac has a unique prodrug structure and is converted to a potent cyclo-oxygenase inhibitor, amfenac, by intraocular hydrolases (see Figure 1 ). 6, 7 Upon ocular dosing, nepafenac permeates the cornea, is metabolised by intraocular tissues 8 and is converted into amfenac for optimal efficacy. The prodrug mechanism of action maximises bioactivation to amfenac in the iris, ciliary body, retina, choroid and cornea to a lesser extent, making nepafenac a target-specific NSAID. 9 Experimental studies on nepafenac demonstrated properties of enhanced permeability and rapid bioactivation to amfenac, to inhibit PG synthesis in the anterior and posterior eye segments. 7 Furthermore, from a safety standpoint, preclinical studies have shown that the Anterior Segment Cataract Surgery prodrug structure minimises surface accumulation, as it is rapidly distributed to the anterior chamber and to posterior segment tissues.
Thus, ocular surface complications associated with conventional NSAID treatments may be minimised. 9 Cornea, anterior and posterior segment safety were studied in vivo via slit lamp biomicroscopic examination in two long-term preclinical trials, with no ocular or systemic toxicity. Figure 2 ).
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Furthermore, high and sustained concentrations of the prodrug were observed in the conjunctiva, cornea and sclera, suggesting a depot for continued hydrolysis to amfenac. Low vitreous concentrations of both drugs indicated that posterior segment likely received the drug via trans-scleral penetration. 12 A multicentre investigative study evaluating the aqueous humour concentrations and COX inhibitory activities of nepafenac, amfenac, ketorolac and bromfenac following topical ocular administration in patients having cataract surgery, found that nepafenac had greater ocular bioavailability than any other drug tested (see Figure 3) . 13 Nepafenac had the shortest time to peak concentration and greatest peak aqueous humour concentration. Additionally, both the C max and the area under the curve (AUC) of nepafenac were significantly larger than the other drugs tested (P<0.05).
Anterior Segment Efficacy
Nepafenac is indicated for prevention of pain and inflammation in the anterior segment following cataract surgery with intraocular lens (IOL) implantation. A randomised double-blind vehicle-controlled trial was designed to examine whether nepafenac, as a sole treatment, decreases the incidence and severity of pain and inflammation following cataract surgery with IOL implantation. 14 A total of 476 patients were included in the study, and a much higher percentage of patients (83.1-93.0 %) in the nepafenac group (n=243) were pain-free at all visits as compared with vehicle-treated patients (41.6-46.4 %) (n=233).
A greater number of patients in the nepafenac group were cured at day 14 (see Figure 4) . Additionally, the nepafenac treated patient group had lower signs of inflammation (aqueous cells scores, mean aqueous flare scores and mean aqueous cells plus flare scores) supporting that nepafenac is effective in preventing inflammation (see Figure 5 ).
Similar results were observed in a multicentre, randomised, double-masked clinical study, comparing nepafenac, ketorolac and placebo. 15 A total of 227 patients undergoing cataract surgery were randomised to receive nepafenac (n=77), ketorolac (n=73), or placebo (n=77), one day pre-operatively and for 21 days post-operatively. When compared with placebo, nepafenac produced significantly more cures at day 14, more clinical successes from day 7 onward, and more pain-free patients from day three onward. Nepafenac was also superior to ketorolac in terms of clinical success at day 14 and in percentage of pain-free patients at day three. Compared with ketorolac, nepafenac showed less discomfort upon instillation.
Posterior Segment Efficacy -Results from Preclinical Studies
To evaluate efficacy of nepafenac in the posterior chamber of the eye, a preclinical study was performed using a rabbit model of inflammation-mediated retinal oedema. 16 Pan-retinal inflammation was induced using intravitreal injection of the mitogen concanavalin A, and 
Prevention of Macular Oedema in Diabetic Patients after Cataract Surgery
In diabetic patients, macular oedema (MO) is a frequent cause of unfavourable visual outcome following cataract surgery. 17 Estimates of the rate of MO in diabetic patients following cataract surgery are variable and range from 31 to 81 % at assorted time-points post-surgery. 
Safety and Tolerability
Although corneal complications following NSAID use are uncommon, 22 NSAIDs have been associated with corneal effects, such as keratitis and involved in clinical studies experienced adverse reactions when receiving nepafenac, leading to discontinuation in 0.6 % of patients. 23 This was less, however, than the discontinuation of patients receiving placebo (1.3 %). No serious adverse events were reported in these studies. In the multicentre, randomised, double-masked clinical study comparing nepafenac, ketorolac and placebo, at the day 7 visit only, mean ocular discomfort was significantly lower for nepafenac 0.1 % compared with ketorolac 0.5 % (p=0.0158) and lower but not significantly in respect to placebo (see Figure 6 ). Source: Nardi, et al., 2007. 15 
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